Mechanistische Analysen zu Krankheits-korrelierten SNPs in ...

7 Literaturverzeichnis
R.: A Pumilio-induced RNA structure switch in p27-3’ UTR controls miR-221 and miR-222
accessibility. In: Nat Cell Biol 12 (2010), S. 1014–20
[179] WAGNER, E. G. ; SIMONS, R. W.: Antisense RNA control in bacteria, phages, and plasmids. In:
Annu Rev Microbiol 48 (1994), S. 713–742
[180] FRANCH, T. ; PETERSEN, M. ; WAGNER, E. G. ; JACOBSEN, J. P. ; GERDES, K.: Antisense
RNA regulation in prokaryotes: rapid RNA/RNA interaction facilitated by a general U-turn loop
structure. In: J Mol Biol 294 (1999), S. 1115–1125
[181] SCHWARZ, D. S. ; DING, H. ; KENNINGTON, L. ; MOORE, J. T. ; SCHELTER, J. ; BURCHARD, J. ;
LINSLEY, P. S. ; ARONIN, N. ; XU, Z. ; ZAMORE, P. D.: Designing siRNA that distinguish between
genes that differ by a single nucleotide. In: PLoS Genet 2 (2006), S. e140
[182] CHENG, C. ; BHARDWAJ, N. ; GERSTEIN, M.: The relationship between the evolution of microR-
NA targets and the length of their UTRs. In: BMC Genomics 10 (2009), S. 431
[183] REICH, S. J. ; FOSNOT, J. ; KUROKI, A. ; TANG, W. ; YANG, X. ; MAGUIRE, A. M. ; BENNETT, J.
; TOLENTINO, M. J.: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular
neovascularization in a mouse model. In: Mol Vis 9 (2003), S. 210–216
[184] OPKO HEALTH INC.: http://www.opko.com/research/?doc=ophthalmics. – Abrufdatum:
08.06.2012
[185] STRUMBERG, D. ; SCHULTHEIS, B. ; MEYER-SABELLEK, W. ; VANK, C. ; GEBHARDT, F. ; SANTEL,
A. ; KEIL, O. ; GIESE, K. ; KAUFMANN, J. ; DREVS, J.: Antimetastatic activity of Atu027, a
liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results
of a phase I study in patients with advanced solid tumors. In: J Clin Oncol 30, 2012 (suppl;
abstr e13597), 2012
[186] LANFORD, R. E. ; HILDEBRANDT-ERIKSEN, E. S. ; PETRI, A. ; PERSSON, R. ; LINDOW, M. ;
MUNK, M. E. ; KAUPPINEN, S. ; ØRUM, H.: Therapeutic silencing of microRNA-122 in primates
with chronic hepatitis C virus infection. In: Science 327 (2010), S. 198–201
[187] SANTARIS PHARMA A/S: http://www.santaris.com/product-pipeline/drug-candidates/
infectious-diseases. – Abrufdatum: 08.06.2012
[188] THE HUNTINGTON’S DISEASE COLLABORATIVE RESEARCH GROUP: A novel gene containing a
trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. In:
Cell 72 (1993), S. 971–983
[189] PFISTER, E. L. ; KENNINGTON, L. ; STRAUBHAAR, J. ; WAGH, S. ; LIU, W. ; DIFIGLIA, M. ;
LANDWEHRMEYER, B. ; VONSATTEL, J. P. ; ZAMORE, P. D. ; ARONIN, N.: Five siRNAs targeting
three SNPs may provide therapy for three-quarters of Huntington’s disease patients. In: Curr
Biol 19 (2009), S. 774–8
[190] SCHOLEFIELD, J. ; GREENBERG, L. J. ; WEINBERG, M. S. ; ARBUTHNOT, P. B. ; ABDELGANY, A. ;
WOOD, M. J.: Design of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction
of a SCA7 phenotype. In: PLoS One 4 (2009), S. e7232
[191] MÜLLER, G. A. ; HANSEN, U. ; XU, Z. ; GRISWOLD, B. ; TALAN, M. I. ; MCDONNELL, N. B. ;
BRIEST, W.: Allele-specific siRNA knockdown as a personalized treatment strategy for vascular
Ehlers-Danlos syndrome in human fibroblasts. In: FASEB J 26 (2012), S. 668–677
[192] WANG, Z.: MicroRNA Interference Technologies Chapter 4: miRNA Mimic Technology.
Springer-Verlag Berlin Heidelberg, 2009
[193] XIAO, J. ; YANG, B. ; LIN, H. ; LU, Y. ; LUO, X. ; WANG, Z.: Novel approaches for gene-specific
interference via manipulating actions of microRNAs: examination on the pacemaker channel
genes HCN2 and HCN4. In: J Cell Physiol 212 (2007), S. 285–292
164